Open AccessRisk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy‐induced amenorrhea
Author(s) -
Chung Clement
Publication year - 2017
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/caac.21415
Subject(s) - medicine , tamoxifen , aromatase inhibitor , amenorrhea , breast cancer , aromatase , oncology , chemotherapy , anastrozole , adjuvant , adjuvant therapy , follicle stimulating hormone , gynecology , hormone , cancer , luteinizing hormone , pregnancy , biology , genetics
Key Points In this study, the risk of a return to menses and/or premenopausal estradiol/follicle‐stimulating hormone levels by 30 months after a switch from adjuvant tamoxifen to aromatase inhibitor therapy in women with postmenopausal estradiol levels at the time of the switch was 15.2% (38 of 250 patients) for women who had chemotherapy‐induced amenorrhea and were aged younger than 50 years at the time of breast cancer diagnosis. The risk was 1.2% (1 in 79 women) for women who were aged 50 to 54 years but still were premenopausal at the time of breast cancer diagnosis.